Psyence Biomedical (PBM) Stock Soars 200%+ on White House Ibogaine Executive Order

Key Highlights

• Shares of PBM surged as much as 203.8% on April 16, 2026, following reports that the White House plans to issue an executive order promoting ibogaine research.
• Psyence Biomedical announced the expansion of its Australian clinical trial infrastructure from three to five locations for its NPX-5 Phase IIb psilocybin program.
• The biotech firm postponed a planned 1-for-6.25 reverse stock split, allowing shares to continue trading without adjustment.
• Market watchers view the rally as speculative momentum amplified by low liquidity rather than fundamental catalyst strength.
• With a market capitalization of only $11.63 million and a GF Score of 20/100, PBM remains highly speculative with a profitability score of just 1/10.

On April 16, 2026, Psyence Biomedical (PBM) delivered one of the most dramatic single-day performances in the psychedelic biotech sector. Shares rocketed more than 200% as traders reacted to breaking news that the White House is working on an executive order designed to advance ibogaine research, a compound being explored for PTSD and addiction treatment.

Psyence Biomedical Ltd., PBM

According to Quiver PriceTracker, PBM finished the trading day up roughly 203.8%. GuruFocus data indicated intraday peaks reached approximately 105.96%.

The anticipated White House directive represents a meaningful policy evolution in federal attitudes toward psychedelic medicine. Ibogaine, which has garnered attention for its potential in addressing substance use disorders and psychological trauma, would receive expanded federal support for clinical investigation.

While Psyence Biomedical’s primary focus is natural psilocybin rather than ibogaine, the broader legitimization of psychedelic therapies created a sector-wide wave that carried PBM significantly higher.

Australian Trial Sites Double in Strategic Expansion

Beyond the macroeconomic catalyst, Psyence Biomedical provided company-specific updates that contributed to investor enthusiasm. The firm recently doubled its Australian clinical research footprint, growing from three to five operational sites. This infrastructure enhancement supports the ongoing Phase IIb evaluation of NPX-5, the company’s naturally derived psilocybin candidate being studied in Adjustment Disorder among cancer patients in palliative settings.

The additional sites are intended to accelerate participant enrollment and maintain continuous dosing schedules throughout the trial. These operational details were disclosed through an SEC Form 6-K filing submitted in April 2026.

Notably, no fresh efficacy or safety results were announced on April 16. Market analysts characterized the price action as momentum-driven speculation, magnified by limited share liquidity.

Additionally, Psyence Biomedical confirmed the postponement of a previously scheduled 1-for-6.25 reverse stock split. Shares will continue trading at their current structure until management establishes a new implementation timeline. This decision maintained the existing float size, potentially contributing to the volatility and rapid price appreciation observed.

Financial Profile and Investor Positioning

Psyence Biomedical operates as a micro-cap entity with a total market valuation of approximately $11.63 million. Prior to the surge, shares were changing hands near $5.08—significantly below the 52-week peak of $74.94.

The company’s GF Score registers at 20 out of a possible 100. While financial strength receives a respectable 8/10 rating, profitability scores a minimal 1/10. The absence of a price-to-earnings ratio reflects ongoing losses.

Institutional engagement remains limited. During Q4 2025, five institutional holders reduced or eliminated their positions entirely. Parallel Advisors divested its complete stake of 151,250 shares. UBS Group represented the sole new institutional entrant, acquiring 1,007 shares.

Insider transaction activity has been absent over the trailing twelve-month period.

The company maintains a federally licensed psilocybin cultivation operation in Southern Africa, supplying material to international research collaborators.

As of April 16, 2026, Psyence Biomedical has yet to generate revenue or achieve profitability, with its clinical development programs still navigating mid-stage evaluation phases.